CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Clinical trial NCT05207722 · TERMINATED
Trial details
- NCT number
- NCT05207722
- Sponsor
- Celularity Incorporated
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-14
- Primary completion
- 2024-02-15
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.